ArticleExperimental and therapeutic medicine2025
Cardiac light chain amyloidosis secondary to Waldenström's macroglobulinemia: A case report and review.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac light chain amyloidosis (AL) secondary to Waldenström's macroglobulinemia (WM) presents a complex challenge in medical practice due to its rarity and diagnostic difficulty. A 67-year-old male presented with symptoms of heart failure and was diagnosed with cardiac AL amyloidosis secondary to WM. The diagnosis of WM was confirmed through a combination of immunoglobulin (Ig) profile with abnormal IgM levels, bone marrow morphology, immunofixation electrophoresis, serum protein electrophoresis and gene mutation analysis. Cardiac amyloidosis was identified through cardiac echocardiography and confirmed through positive Congo red staining of bone marrow and apple green color transformation of an abdominal fat biopsy. The amyloid protein mass spectrometry indicated that the type of cardiac involvement was AL amyloidosis. The patient responded positively to the BR and BRD chemotherapy regimens but only showed a partial response (PR). In conclusion, a patient with WM-AL amyloidosis was diagnosed based on the presence of abnormal IgM paraprotein levels and the high Igλ C2 peak in the amyloid protein mass spectrometry. The BR (0.15 g bendamustine on days 2-3, 0.6 g rituximab on day 1) and BRD (2 mg bortezomib once a week for 4 weeks, 0.5 g rituximab on day 1 and 10 mg dexamethasone once a week for 4 weeks) chemotherapy regimens only achieved a partial response due to the existing irreversible organ impairment of the heart with chronic heart failure. The diagnosis of WM combined with cardiac AL amyloidosis is a challenge, and thus, it is necessary to improve clinical vigilance and early detection. Therapeutic strategies tailored to the individual patient's clinical profile are essential for optimizing outcomes, given the limited consolidated treatment evidence available for this rare condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.